Limits...
The promise of circulating tumor cell analysis in cancer management.

Mateo J, Gerlinger M, Rodrigues DN, de Bono JS - Genome Biol. (2014)

Bottom Line: Enumeration and molecular characterization of circulating tumor cells isolated from peripheral blood of patients with cancer can aid selection of targeted therapy for patients, monitoring of response to therapies and optimization of drug development, while also providing valuable information about intratumoral heterogeneity.

View Article: PubMed Central - PubMed

ABSTRACT
Enumeration and molecular characterization of circulating tumor cells isolated from peripheral blood of patients with cancer can aid selection of targeted therapy for patients, monitoring of response to therapies and optimization of drug development, while also providing valuable information about intratumoral heterogeneity.

Show MeSH

Related in: MedlinePlus

Prognostic and predictive value of circulating tumor cell (CTC) counts in metastatic castration-resistant prostate cancer (mCRPC). (a) Survival curves (Kaplan-Meier) of a group of 276 patients with mCRPC who were about to start a new line of chemotherapy, showing how patients with <5 CTCs per 7.5 ml blood (‘favorable’ CTC count; green line) had a better prognosis than the group of patients with higher counts (red line). (b) Differential survival curves representing outcomes for patients according to the change in their CTC counts after receiving treatment, which show that patients with a conversion from an ‘unfavorable’ to a ‘favorable’ count during the response to treatment (blue line) experience longer survival than those without a CTC drop (red and orange lines). The green line is the survival curves for those patients who have low CTC counts at the beginning to that study and whose counts remained low throughout the study. OS, overall survival; HR, Haza-ratio; CI, confidence interval. Reprinted from [13] de Bono JS et al. Clin Cancer Res 2008, 14:6302-6309. (Copyright by American Association for Cancer Research).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4281949&req=5

Fig2: Prognostic and predictive value of circulating tumor cell (CTC) counts in metastatic castration-resistant prostate cancer (mCRPC). (a) Survival curves (Kaplan-Meier) of a group of 276 patients with mCRPC who were about to start a new line of chemotherapy, showing how patients with <5 CTCs per 7.5 ml blood (‘favorable’ CTC count; green line) had a better prognosis than the group of patients with higher counts (red line). (b) Differential survival curves representing outcomes for patients according to the change in their CTC counts after receiving treatment, which show that patients with a conversion from an ‘unfavorable’ to a ‘favorable’ count during the response to treatment (blue line) experience longer survival than those without a CTC drop (red and orange lines). The green line is the survival curves for those patients who have low CTC counts at the beginning to that study and whose counts remained low throughout the study. OS, overall survival; HR, Haza-ratio; CI, confidence interval. Reprinted from [13] de Bono JS et al. Clin Cancer Res 2008, 14:6302-6309. (Copyright by American Association for Cancer Research).

Mentions: In metastatic castration-resistant prostate cancer (mCRPC), the prognostic value of baseline CTC counts was first assessed in the IMMC38 trial, a study including 164 patients about to start first-line chemotherapy (81% received docetaxel, and the remainder received a docetaxel-containing regimen). A high count of CTCs at baseline (defined as ≥5 CTCs in 7.5 ml blood) was associated with a significantly shorter survival compared with having low counts at baseline (11.5 versus 21.7 months; P < 0.0001). CTC counts were better indicators of survival than levels of prostate-specific antigen (PSA) (Figure 2) [13,22]. Further clinical trials in mCRPC have confirmed these findings [23].Figure 2


The promise of circulating tumor cell analysis in cancer management.

Mateo J, Gerlinger M, Rodrigues DN, de Bono JS - Genome Biol. (2014)

Prognostic and predictive value of circulating tumor cell (CTC) counts in metastatic castration-resistant prostate cancer (mCRPC). (a) Survival curves (Kaplan-Meier) of a group of 276 patients with mCRPC who were about to start a new line of chemotherapy, showing how patients with <5 CTCs per 7.5 ml blood (‘favorable’ CTC count; green line) had a better prognosis than the group of patients with higher counts (red line). (b) Differential survival curves representing outcomes for patients according to the change in their CTC counts after receiving treatment, which show that patients with a conversion from an ‘unfavorable’ to a ‘favorable’ count during the response to treatment (blue line) experience longer survival than those without a CTC drop (red and orange lines). The green line is the survival curves for those patients who have low CTC counts at the beginning to that study and whose counts remained low throughout the study. OS, overall survival; HR, Haza-ratio; CI, confidence interval. Reprinted from [13] de Bono JS et al. Clin Cancer Res 2008, 14:6302-6309. (Copyright by American Association for Cancer Research).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4281949&req=5

Fig2: Prognostic and predictive value of circulating tumor cell (CTC) counts in metastatic castration-resistant prostate cancer (mCRPC). (a) Survival curves (Kaplan-Meier) of a group of 276 patients with mCRPC who were about to start a new line of chemotherapy, showing how patients with <5 CTCs per 7.5 ml blood (‘favorable’ CTC count; green line) had a better prognosis than the group of patients with higher counts (red line). (b) Differential survival curves representing outcomes for patients according to the change in their CTC counts after receiving treatment, which show that patients with a conversion from an ‘unfavorable’ to a ‘favorable’ count during the response to treatment (blue line) experience longer survival than those without a CTC drop (red and orange lines). The green line is the survival curves for those patients who have low CTC counts at the beginning to that study and whose counts remained low throughout the study. OS, overall survival; HR, Haza-ratio; CI, confidence interval. Reprinted from [13] de Bono JS et al. Clin Cancer Res 2008, 14:6302-6309. (Copyright by American Association for Cancer Research).
Mentions: In metastatic castration-resistant prostate cancer (mCRPC), the prognostic value of baseline CTC counts was first assessed in the IMMC38 trial, a study including 164 patients about to start first-line chemotherapy (81% received docetaxel, and the remainder received a docetaxel-containing regimen). A high count of CTCs at baseline (defined as ≥5 CTCs in 7.5 ml blood) was associated with a significantly shorter survival compared with having low counts at baseline (11.5 versus 21.7 months; P < 0.0001). CTC counts were better indicators of survival than levels of prostate-specific antigen (PSA) (Figure 2) [13,22]. Further clinical trials in mCRPC have confirmed these findings [23].Figure 2

Bottom Line: Enumeration and molecular characterization of circulating tumor cells isolated from peripheral blood of patients with cancer can aid selection of targeted therapy for patients, monitoring of response to therapies and optimization of drug development, while also providing valuable information about intratumoral heterogeneity.

View Article: PubMed Central - PubMed

ABSTRACT
Enumeration and molecular characterization of circulating tumor cells isolated from peripheral blood of patients with cancer can aid selection of targeted therapy for patients, monitoring of response to therapies and optimization of drug development, while also providing valuable information about intratumoral heterogeneity.

Show MeSH
Related in: MedlinePlus